JLE

Hépato-Gastro & Oncologie Digestive

MENU

Biopsies and cancer patient decision making Volume 17, issue 5, septembre-octobre 2010

Figures

See all figures

Author
Unité d'oncologie uro-digestive, CHU Charles Nicolle, 1 rue de Germont, 76000 Rouen

Complementary molecular analysis to pathology assessment is now recommended in digestive oncology. The aim of these analyses of the tumoral tissue is the detection of prognosis and/or predictive alteration that might be useful in clinical practice. To date, four tests are commonly performed: HER2 expression for trastuzumab in a metastatic gastric cancer, KIT mutations for imatinib in gastrointestinal tumours, microsatellite instability for adjuvant treatment in colorectal cancer, and KRAS mutation for anti-EGFR therapies in metastatic colorectal cancer. For the other malignancies of the gastrointestinal tract, no additional test should be performed in routine basis.